Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Epstein-Barr virus specific antibodies in patients with coeliac disease

Summary

SERUM antibodies to Epstein-Barr viral antigens were studied in 56 patients with treated coeliac disease and 53 healthy controls. Four individuals with a malignancy were among the group studied.

Twenty-one patients (37.5%) showed unusual antibody response patterns which were broadly divisible into two groups: (1) those with elevated antiviral capsid antigen (VCA), antibodies associated with positive anti-early antigen (EA) responses, and (2) those with low anti-Epstein-Barr nuclear antigen (EBNA) responses. While the results indicate that some patients with coeliac disease have an immunological abnormality with respect to EBV, there is as yet no direct evidence that this results in malignancies.

This is a preview of subscription content, log in to check access.

References

  1. Cooper, B. T., Holmes, G. K. T., Ferguson, R. and Cooke, W. T. 1980. Coeliac disease and malignancy. Medicine (Baltimore) 59, 249.

  2. Cornell, G. J. and Townley, R. R. W. 1973. Investigation of possible intestinal peptidase in coeliac disease. Clin. Chim. Acta 43, 113.

  3. Falchuk, Z. M. and Strober, W. 1974. Glutensensitive enteropathy: Synthesis of antigliadin antibodyin vitro. Gut 15, 947.

  4. Filipovich, A. H., Spector, B. C. and Kersey, J. 1980. Immunodeficiency in humans as a risk factor in the development of malignancy. Prevent. Med. 9, 252.

  5. Hanto, D. W., Sakamoto, K., Purtilo, D. T.et al. 1981. The Epstein-Barr Virus in the pathogenesis of post-transplant lymphoproliferative disorders. Surgery 90, 204.

  6. Harada, S., Bechtold, T., Seely, J. K. and Purtilo, D. T. 1982. Cell-mediated immunity to Epstein-Barr Virus (EBV) and natural killer (NK)-cell activity in the X-linktd lymphoproliferative syndrome. Int. J. Cancer 30, 739.

  7. Harada, S., Tatsumi, E., Lipscombe, H. and Purtilo, D. T. 1983. Responses to Epstein-Barr virus in immune deficiency patients. In Immune Deficiency and Cancer: Epstein-Barr Virus and Lymphoproliferative malignancies. Edited by D. T. Purtilo. Plenum Press, New York.

  8. Harada, S., Meuwissen, H., Bechtold, T.et al. 1984. Comparative study of immune responses to Epstein-Barr Virus of patients with X-linked lymphoproliferative syndrome (XLP) and Wiskott-Aldrich syndrome (WAS). Submitted for publication.

  9. Henle, W., Henle, G. and Horwitz, C. A. 1974. Epstein-Barr virus-specific diagnostic tests in infectious mononucleosis. Hum. Path. 5, 551.

  10. Henle, W. and Henle, G. 1981. Epstein-Barr Virusspecific serology in immunologically compromised individuals. Cancer Res. 41, 4222.

  11. Henle, W., Ho, H. C. and Kwan, H. C. 1973. Antibodies to Epstein-Barr Virus-related antigens in nasopharyngeal carcinoma. Comparison of active case with long-term survivors JNCI 51 361.

  12. Purtilo, D. T. 1981. Immune deficiency predisposing to Eustein Barr virus-induced lymphoproliferative disease: The X-linked lymphoproliferative syndrome as a model. In Advances in Cancer Research. Edited by G. Klein and S. Weinhouse. Academic Press, New York. 279.

  13. Purtilo, D. T., Sakamoto, K., Barnabei, V.et al. 1982. Epstein-Barr Virus-induced disease in boys with X-linked lymphoproliferative syndrome (XLP). Update on the studies of the registry. Am. J. Med. 73, 49.

  14. Reedman, B. M. and Klein, G. 1973. Cellular location of an Epstein-Barr virus (EVV)-associated complement-fixing antigen in producer and non producer lymphoblastoid cell lines. Int. J. Cancer 11, 499.

  15. Saemundsen, A. K., Purtilo, D. T., Sakamoto, K.et al. 1981. Documentation of Epstein-Barr Virus infection in immunodeficient patients with life-threatening lymphoproliferative disease by Epstein-Barr Virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res. 41, 4237.

  16. Sakmoto, K., Freed, H. F. and Purtilo, D. T. 1980. Antibody responses to Epstein-Barr virus in families with X-linked lymphoproliferative syndrome. J. Immunol. 125, 921.

  17. Sakamoto, K., Aiba, M., Katayama, I.et al. 1981. Antibodies to Epstein-Barr Virus-specific antigens in patients with hairy-cell leukaemia. Int. J. Cancer 27, 453.

  18. Sakamoto, K., Seely, J. K., Lindsten, T.et al. 1982. Abnormal anti-Epstein-Barr virus antibodies in carriers of the X-linked lymphoproliferative syndrome and in females at risk. J. Immunol. 128, 904.

  19. Swinson, C. M., Slavin, G., Coles, E. C. and Booth, C. C. 1983. Coeliac disease and malignancy. Lancet 15, 111.

  20. Tobi, M., Morag, A., Ravid, I.et al. 1982. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr Virus infection. Lancet 9, 61.

Download references

Author information

Correspondence to Shinji Harada or John Greally or Jack Davis or Nancy Synder or Fiona Stevens or Claran McCarthy or David T. Purtilo.

Additional information

We thank Miss Patricia Rohan for typing this manuscript.

Supported in part by a grant from the Cancer Research Advancement Board of the Irish Cancer Society and by PHS grant number 30196, awarded by the National Cancer Institute, DHHS, the American Society RD161, the Nebraska Department of Health, and the Lymphoproliferative Research Fund.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Harada, S., Greally, J., Davis, J. et al. Epstein-Barr virus specific antibodies in patients with coeliac disease. I.J.M.S. 154, 416–421 (1985). https://doi.org/10.1007/BF02937215

Download citation

Keywords

  • Coeliac Disease
  • Hairy Cell Leukemia
  • Ataxia Telangiectasia
  • Geometrical Mean Titre
  • Viral Capsid Antigen